{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:18:32Z","timestamp":1793121512911,"version":"4.5.0"},"reference-count":139,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Metabolic dysfunction-associated fatty liver disease (MAFLD) has become the most prevalent chronic liver disorder worldwide, encompassing a spectrum that ranges from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH) and hepatic fibrosis. However, its precise pathogenic mechanisms remain incompletely understood, and effective, specific pharmacological treatments are still lacking. Disruption of hepatic lipid metabolic homeostasis represents a central event in the onset and progression of MAFLD. With advances in lipidomics and metabolomics, researchers can now more accurately delineate the aberrant accumulation of specific lipid species within hepatocytes and their pivotal roles in triggering insulin resistance, oxidative stress, and inflammatory responses. This review systematically summarizes the core mechanisms by which hepatic lipid metabolic dysregulation drives MAFLD progression and highlights recent advances in therapeutic strategies targeting lipotoxic pathways, metabolic reprogramming, and related molecular targets. These insights aim to provide a theoretical basis and new perspectives for future research and clinical intervention in this field.<\/jats:p>","DOI":"10.3389\/fendo.2026.1785178","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:39:25Z","timestamp":1773812365000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Lipid metabolism-MAFLD crosstalk: mechanisms and therapy"],"prefix":"10.3389","volume":"17","author":[{"given":"Bojia","family":"Li","sequence":"first","affiliation":[{"name":"Basic Medical College, Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengai","family":"Piao","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Fu","sequence":"additional","affiliation":[{"name":"Basic Medical College, Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Fu","sequence":"additional","affiliation":[{"name":"Basic Medical College, Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyao","family":"Qin","sequence":"additional","affiliation":[{"name":"Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weitai","family":"Kong","sequence":"additional","affiliation":[{"name":"Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yidi","family":"Ma","sequence":"additional","affiliation":[{"name":"Basic Medical College, Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[{"name":"Basic Medical College, Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Fang","sequence":"additional","affiliation":[{"name":"Basic Medical College, Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyang","family":"Hu","sequence":"additional","affiliation":[{"name":"Basic Medical College, Heilongjiang University of Chinese Medicine","place":["Harbin, Heilongjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0367","article-title":"MAFLD: How is it different from NAFLD","volume":"29","author":"Gofton","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-023-01242-8","article-title":"Mechanisms linking metabolic-associated fatty liver disease (MAFLD) to cardiovascular disease","volume":"25","author":"Badmus","year":"2023","journal-title":"Curr Hypertens Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-042220-020407","article-title":"Fatty liver disease: Diagnosis and stratification","volume":"73","author":"Saiman","year":"2022","journal-title":"Annu Rev Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31150","article-title":"Epidemiological features of NAFLD from 1999 to 2018 in China","volume":"71","author":"Zhou","year":"2020","journal-title":"Hepatology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: Clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.07.031","article-title":"Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD","volume":"80","author":"De","year":"2024","journal-title":"J Hepatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"7940","DOI":"10.1038\/s41467-022-35481-1","article-title":"Pharmacological inhibition of Lin28 promotes ketogenesis and restores lipid homeostasis in models of non-alcoholic fatty liver disease","volume":"13","author":"Lekka","year":"2022","journal-title":"Nat Commun"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3067","DOI":"10.1038\/s41467-020-16918-x","article-title":"Hepatic HuR modulates lipid homeostasis in response to high-fat diet","volume":"11","author":"Zhang","year":"2020","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101092","article-title":"Dysregulated lipid metabolism links NAFLD to cardiovascular disease","volume":"42","author":"Deprince","year":"2020","journal-title":"Mol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222111905","article-title":"Clinical and molecular biomarkers for diagnosis and staging of NAFLD","volume":"22","author":"Di Mauro","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.73890","article-title":"Covalent inhibition of pyruvate kinase M2 reprograms metabolic and inflammatory pathways in hepatic macrophages against non-alcoholic fatty liver disease","volume":"18","author":"Fan","year":"2022","journal-title":"Int J Biol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1460280","article-title":"Association between nontraditional lipid parameters and the risk of type 2 diabetes and prediabetes in patients with nonalcoholic fatty liver disease: From the national health and nutrition examination survey 2017-2020","volume":"15","author":"Liu","year":"2024","journal-title":"Front Endocrinol Lausanne"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2023.109414","article-title":"Quercetin ameliorates nonalcoholic fatty liver disease (NAFLD) via the promotion of AMPK-mediated hepatic mitophagy","volume":"120","author":"Cao","year":"2023","journal-title":"J Nutr Biochem"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101115","article-title":"Hepatic lipid droplets: A balancing act between energy storage and metabolic dysfunction in NAFLD","volume":"50","author":"Mashek","year":"2021","journal-title":"Mol Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13061422","article-title":"Orchestration of gut-liver-associated transcription factors in MAFLD: From cross-organ interactions to therapeutic innovation","volume":"13","author":"Liu","year":"2025","journal-title":"Biomedicines"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-021-00501-9","article-title":"Non-alcoholic fatty liver disease: The interplay between metabolism, microbes and immunity","volume":"3","author":"Tilg","year":"2021","journal-title":"Nat Metab"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/j.cell.2024.02.024","article-title":"A gut-derived hormone regulates cholesterol metabolism","volume":"187","author":"Hu","year":"2024","journal-title":"Cell"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2022.09.023","article-title":"The role of lipids in cancer progression and metastasis","volume":"34","author":"Martin-Perez","year":"2022","journal-title":"Cell Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adc9317","article-title":"Brain lipidomics: From functional landscape to clinical significance","volume":"8","author":"Yoon","year":"2022","journal-title":"Sci Adv"},{"key":"B20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.tcb.2024.04.008","article-title":"Role of lipids in interorganelle communication","volume":"35","author":"Domingues","year":"2025","journal-title":"Trends Cell Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.108873","article-title":"Mitochondria-rough-ER contacts in the liver regulate systemic lipid homeostasis","volume":"34","author":"Anastasia","year":"2021","journal-title":"Cell Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2114739119","article-title":"Triglyceride breakdown from lipid droplets regulates the inflammatory response in macrophages","volume":"119","author":"van Dierendonck","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.plipres.2023.101235","article-title":"Lipid metabolism around the body clocks","volume":"91","author":"Petrenko","year":"2023","journal-title":"Prog Lipid Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2021.08.027","article-title":"Lipid metabolism in sickness and in health: Emerging regulators of lipotoxicity","volume":"81","author":"Yoon","year":"2021","journal-title":"Mol Cell"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1097835","article-title":"New insights into the role of dietary triglyceride absorption in obesity and metabolic diseases","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1016\/j.cmet.2024.10.001","article-title":"Amino acid is a major carbon source for hepatic lipogenesis","volume":"36","author":"Liao","year":"2024","journal-title":"Cell Metab"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-021-00440-5","article-title":"SREBP1-induced fatty acid synthesis depletes macrophages antioxidant defences to promote their alternative activation","volume":"3","author":"Bidault","year":"2021","journal-title":"Nat Metab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.202101115","article-title":"ChREBP-driven DNL and PNPLA3 expression induced by liquid fructose are essential in the production of fatty liver and hypertriglyceridemia in a high-fat diet-fed rat model","volume":"66","author":"Vel\u00e1zquez","year":"2022","journal-title":"Mol Nutr Food Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqz046","article-title":"CPT1A-mediated fat oxidation, mechanisms, and therapeutic potential","volume":"161","author":"Schlaepfer","year":"2020","journal-title":"Endocrinology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"4987","DOI":"10.1038\/s41467-023-40597-z","article-title":"p21-activated kinase 4 suppresses fatty acid \u03b2-oxidation and ketogenesis by phosphorylating NCoR1","volume":"14","author":"Shi","year":"2023","journal-title":"Nat Commun"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168969","article-title":"Mechanisms mediating the regulation of peroxisomal fatty acid beta-oxidation by PPAR\u03b1","volume":"22","author":"Tahri-Joutey","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2023.101701","article-title":"Basal re-esterification finetunes mitochondrial fatty acid utilization","volume":"71","author":"Sharma","year":"2023","journal-title":"Mol Metab"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2024.102048","article-title":"FITM2 deficiency results in ER lipid accumulation, ER stress, and reduced apolipoprotein B lipidation and VLDL triglyceride secretion in vitro and in mouse liver","volume":"90","author":"Wang","year":"2024","journal-title":"Mol Metab"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-019-0250-7","article-title":"Regulation of intestinal lipid metabolism: Current concepts and relevance to disease","volume":"17","author":"Ko","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.semcdb.2020.04.011","article-title":"Hepatic lipid droplet homeostasis and fatty liver disease","volume":"108","author":"Seebacher","year":"2020","journal-title":"Semin Cell Dev Biol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2023.08.001","article-title":"Novel approach using [18F]FTHA-PET and de novo synthesized VLDL for assessment of FFA metabolism in a rat model of diet induced NAFLD","volume":"42","author":"Ustsinau","year":"2023","journal-title":"Clin Nutr"},{"key":"B37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s10020-019-0085-2","article-title":"miR-122 promotes hepatic lipogenesis via inhibiting the LKB1\/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease","volume":"25","author":"Long","year":"2019","journal-title":"Mol Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15099","article-title":"Astaxanthin attenuates hepatic damage and mitochondrial dysfunction in non-alcoholic fatty liver disease by up-regulating the FGF21\/PGC-1\u03b1 pathway","volume":"177","author":"Wu","year":"2020","journal-title":"Br J Pharmacol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2024.119094","article-title":"VLDL triglycerides and cholesterol in non-alcoholic fatty liver disease and myocardial infarction","volume":"401","author":"Kyhl","year":"2025","journal-title":"Atherosclerosis"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2022.02.015","article-title":"Activation of liver mTORC1 protects against NASH via dual regulation of VLDL-TAG secretion and de novo lipogenesis","volume":"13","author":"Uehara","year":"2022","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115246","article-title":"Meteorin-like alleviates hepatic steatosis by regulating hepatic triglyceride secretion and fatty acid oxidation","volume":"44","author":"Song","year":"2025","journal-title":"Cell Rep"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-022-00924-4","article-title":"Silybin regulates P450s activity by attenuating endoplasmic reticulum stress in mouse nonalcoholic fatty liver disease","volume":"44","author":"Wu","year":"2023","journal-title":"Acta Pharmacol Sin"},{"key":"B43","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41419-020-03003-w","article-title":"Understanding lipotoxicity in NAFLD pathogenesis: Is CD36 a key driver","volume":"11","author":"Rada","year":"2020","journal-title":"Cell Death Dis"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1080\/15548627.2020.1712108","article-title":"SQSTM1\/p62 activates NFE2L2\/NRF2 via ULK1-mediated autophagic KEAP1 degradation and protects mouse liver from lipotoxicity","volume":"16","author":"Lee","year":"2020","journal-title":"Autophagy"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2024.100580","article-title":"Similar insulin regulation of splanchnic FFA and VLDL-TG in men with nonalcoholic hepatic steatosis and steatohepatitis","volume":"65","author":"Risikesan","year":"2024","journal-title":"J Lipid Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1186\/s12876-025-03870-7","article-title":"Correlation between hs-CRP-triglyceride glucose index and NAFLD and liver fibrosis","volume":"25","author":"Zhou","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22084156","article-title":"Role of insulin resistance in MAFLD","volume":"22","author":"Sakurai","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103159","article-title":"SLC7A11-ROS\/\u03b1KG-AMPK axis regulates liver inflammation through mitophagy and impairs liver fibrosis and NASH progression","volume":"72","author":"Lv","year":"2024","journal-title":"Redox Biol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0268","article-title":"TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD","volume":"30","author":"Sun","year":"2024","journal-title":"Clin Mol Hepatol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.cmet.2024.01.011","article-title":"DGAT2 inhibition blocks SREBP-1 cleavage and improves hepatic steatosis by increasing phosphatidylethanolamine in the ER","volume":"36","author":"Rong","year":"2024","journal-title":"Cell Metab"},{"key":"B52","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.cmet.2022.05.004","article-title":"Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia","volume":"34","author":"Morrow","year":"2022","journal-title":"Cell Metab"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/cells10061278","article-title":"Onset of senescence and steatosis in hepatocytes as a consequence of a shift in the diacylglycerol\/ceramide balance at the plasma membrane","volume":"10","author":"Deevska","year":"2021","journal-title":"Cells"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-322509","article-title":"Sphingomyelin synthase 1 mediates hepatocyte pyroptosis to trigger non-alcoholic steatohepatitis","volume":"70","author":"Koh","year":"2021","journal-title":"Gut"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1267\/ahc.14030","article-title":"Roles of oxidized diacylglycerol for carbon tetrachloride-induced liver injury and fibrosis in mouse","volume":"47","author":"Takekoshi","year":"2014","journal-title":"Acta Histochem Cytochem"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/gigascience\/giae023","article-title":"Mechanisms of hepatic steatosis in chickens: integrated analysis of the host genome, molecular phenomics and gut microbiome","volume":"13","author":"Sun","year":"2024","journal-title":"GigaScience"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2023.04.009","article-title":"Schisandra lignans ameliorate nonalcoholic steatohepatitis by regulating aberrant metabolism of phosphatidylethanolamines","volume":"13","author":"Xue","year":"2023","journal-title":"Acta Pharm Sin B"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1172\/JCI151895","article-title":"Inhibiting SCAP\/SREBP exacerbates liver injury and carcinogenesis in murine nonalcoholic steatohepatitis","volume":"132","author":"Kawamura","year":"2022","journal-title":"J Clin Invest"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S351092","article-title":"Didymin ameliorates liver fibrosis by alleviating endoplasmic reticulum stress and glycerophospholipid metabolism: Based on transcriptomics and metabolomics","volume":"16","author":"Li","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamem.2017.04.006","article-title":"The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease","volume":"1859","author":"van der Veen","year":"2017","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"B61","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/hep4.1801","article-title":"Role of cholesterol-associated steatohepatitis in the development of NASH","volume":"6","author":"Horn","year":"2022","journal-title":"Hepatol Commun"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20220681","article-title":"Lysosomal cholesterol overload in macrophages promotes liver fibrosis in a mouse model of NASH","volume":"220","author":"Itoh","year":"2023","journal-title":"J Exp Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30333","article-title":"Mouse Models of Nonalcoholic Steatohepatitis: Toward Optimization of Their Relevance to Human Nonalcoholic Steatohepatitis","volume":"69","author":"Farrell","year":"2019","journal-title":"Hepatology"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2023.1672","article-title":"Protective effects of melatonin in high-fat diet-induced hepatic steatosis via decreased intestinal lipid absorption and hepatic cholesterol synthesis","volume":"38","author":"Ku","year":"2023","journal-title":"Endocrinol Metab Sel"},{"key":"B65","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/nature13475","article-title":"Sphingolipid metabolites in inflammatory disease","volume":"510","author":"Maceyka","year":"2014","journal-title":"Nature"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2023.159333","article-title":"Hepatic deletion of serine palmitoyl transferase 2 impairs ceramide\/sphingomyelin balance, bile acids homeostasis and leads to liver damage in mice","volume":"1868","author":"Lallement","year":"2023","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12331","article-title":"Inhibition of ceramide de novo synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease","volume":"34","author":"Kurek","year":"2014","journal-title":"Liver Int"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202406191","article-title":"Free cholesterol-induced liver injury in non-alcoholic fatty liver disease: Mechanisms and a therapeutic intervention using dihydrotanshinone I","volume":"12","author":"Shou","year":"2025","journal-title":"Adv Sci Weinh"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.07.005","article-title":"Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma","volume":"79","author":"Song","year":"2023","journal-title":"J Hepatol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.2174\/156652410791608225","article-title":"The acid sphingomyelinase\/ceramide pathway: biomedical significance and mechanisms of regulation","volume":"10","author":"Zeidan","year":"2010","journal-title":"Curr Mol Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2009.326","article-title":"Comparison of lipid and fatty acid composition of the liver, subcutaneous and intra-abdominal adipose tissue, and serum","volume":"18","author":"Kotronen","year":"2010","journal-title":"Obes Silv Spring"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3390\/biom12060824","article-title":"NAFLD: Mechanisms, treatments, and biomarkers","volume":"12","author":"Nassir","year":"2022","journal-title":"Biomolecules"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2024.119053","article-title":"Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"400","author":"Iturbe-Rey","year":"2025","journal-title":"Atherosclerosis"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2023.113655","article-title":"Oleic acid improves hepatic lipotoxicity injury by alleviating autophagy dysfunction","volume":"429","author":"Liu","year":"2023","journal-title":"Exp Cell Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26226","article-title":"Mitochondrial adaptations and dysfunctions in nonalcoholic fatty liver disease","volume":"58","author":"Begriche","year":"2013","journal-title":"Hepatology"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mito.2005.10.004","article-title":"Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it","volume":"6","author":"Begriche","year":"2006","journal-title":"Mitochondrion"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-014-1170-1","article-title":"NLRP3 inflammasome activation is required for fibrosis development in NAFLD","volume":"92","author":"Wree","year":"2014","journal-title":"J Mol Med Berl"},{"key":"B79","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrgastro.2016.147","article-title":"NAFLD and diabetes mellitus","volume":"14","author":"Tilg","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00740-6","article-title":"NLRP3 inflammasome activation and cell death","volume":"18","author":"Huang","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2017.91","article-title":"SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology","volume":"13","author":"Shimano","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.09.021","article-title":"Glucose-Mediated N-glycosylation of SCAP Is Essential for SREBP-1 Activation and Tumor Growth","volume":"28","author":"Cheng","year":"2015","journal-title":"Cancer Cell"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202401311","article-title":"Glycerol kinase drives hepatic de novo lipogenesis and triglyceride synthesis in nonalcoholic fatty liver by activating SREBP-1c transcription, upregulating DGAT1\/2 expression, and promoting glycerol metabolism","volume":"11","author":"Ouyang","year":"2024","journal-title":"Adv Sci Weinh"},{"key":"B84","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.freeradbiomed.2019.06.019","article-title":"Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway","volume":"141","author":"Zhu","year":"2019","journal-title":"Free Radic Biol Med"},{"key":"B85","doi-asserted-by":"publisher","first-page":"3820","DOI":"10.1016\/j.molcel.2021.06.003","article-title":"SREBP-1c impairs ULK1 sulfhydration-mediated autophagic flux to promote hepatic steatosis in high-fat-diet-fed mice","volume":"81","author":"Nguyen","year":"2021","journal-title":"Mol Cell"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108065","article-title":"Rotundic acid ameliorates non-alcoholic steatohepatitis via SREBP-1c\/ SCD1 signaling pathway and modulating gut microbiota","volume":"99","author":"Liu","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/cphy.c130024","article-title":"Energy metabolism in the liver","volume":"4","author":"Rui","year":"2014","journal-title":"Compr Physiol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.154113","article-title":"SEMA7AR148W mutation promotes lipid accumulation and NAFLD progression via increased localization on the hepatocyte surface","volume":"7","author":"Zhao","year":"2022","journal-title":"JCI Insight"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106786","article-title":"Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD)","volume":"192","author":"Qiu","year":"2023","journal-title":"Pharmacol Res"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adh9940","article-title":"Integrative multiomic analysis identifies distinct molecular subtypes of NAFLD in a Chinese population","volume":"16","author":"Ding","year":"2024","journal-title":"Sci Transl Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.envint.2023.108138","article-title":"PPAR\u03b1\/ACOX1 as a novel target for hepatic lipid metabolism disorders induced by per- and polyfluoroalkyl substances: An integrated approach","volume":"178","author":"Yang","year":"2023","journal-title":"Environ Int"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113577","article-title":"A new perspective on NAFLD: Focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPAR\u03b1) and farnesoid X receptor (FXR)","volume":"154","author":"Zhou","year":"2022","journal-title":"BioMed Pharmacother"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25115640","article-title":"Metabolic dysfunction-associated steatotic liver disease: From pathogenesis to current therapeutic options","volume":"25","author":"Portincasa","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.10.011","article-title":"\u03b2-Klotho gene variation is associated with liver damage in children with NAFLD","volume":"72","author":"Dongiovanni","year":"2020","journal-title":"J Hepatol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-023-05878-8","article-title":"Tcf7l2 in hepatocytes regulates de novo lipogenesis in diet-induced non-alcoholic fatty liver disease in mice","volume":"66","author":"Lee","year":"2023","journal-title":"Diabetologia"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.07.034","article-title":"Reduced Nogo expression inhibits diet-induced metabolic disorders by regulating ChREBP and insulin activity","volume":"73","author":"Zhang","year":"2020","journal-title":"J Hepatol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcb.2020.151128","article-title":"Causative and sanative dynamicity of ChREBP in hepato-metabolic disorders","volume":"99","author":"Daniel","year":"2020","journal-title":"Eur J Cell Biol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.1038\/s41467-023-41061-8","article-title":"Hyodeoxycholic acid ameliorates nonalcoholic fatty liver disease by inhibiting RAN-mediated PPAR\u03b1 nucleus-cytoplasm shuttling","volume":"14","author":"Zhong","year":"2023","journal-title":"Nat Commun"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2023.07.011","article-title":"Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis","volume":"35","author":"Kuang","year":"2023","journal-title":"Cell Metab"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2024.110024","article-title":"Role of FXR in the development of NAFLD and intervention strategies of small molecules","volume":"757","author":"Long","year":"2024","journal-title":"Arch Biochem Biophys"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11082059","article-title":"The crosstalk between gut microbiota and bile acids promotes the development of non-alcoholic fatty liver disease","volume":"11","author":"Li","year":"2023","journal-title":"Microorganisms"},{"key":"B102","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s40168-023-01709-5","article-title":"Gut microbiota-bile acid crosstalk regulates murine lipid metabolism via the intestinal FXR-FGF19 axis in diet-induced humanized dyslipidemia","volume":"11","author":"Xu","year":"2023","journal-title":"Microbiome"},{"key":"B103","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41522-023-00399-z","article-title":"Gut microbiome determines therapeutic effects of OCA on NAFLD by modulating bile acid metabolism","volume":"9","author":"Liu","year":"2023","journal-title":"NPJ Biofilms Microbiomes"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.09.032","article-title":"Bile acid metabolism and signalling in liver disease","volume":"82","author":"Fuchs","year":"2025","journal-title":"J Hepatol"},{"key":"B105","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jgg.2021.04.002","article-title":"Gut microbiota, inflammation, and molecular signatures of host response to infection","volume":"48","author":"Gou","year":"2021","journal-title":"J Genet Genomics"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1126\/science.aao5774","article-title":"Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes","volume":"359","author":"Zhao","year":"2018","journal-title":"Science"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15024","article-title":"Diet and exercise in NAFLD\/NASH: Beyond the obvious","volume":"41","author":"Semmler","year":"2021","journal-title":"Liver Int"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118868","article-title":"Aerobic training improves NAFLD markers and insulin resistance through AMPK-PPAR-\u03b1 signaling in obese mice","volume":"266","author":"Diniz","year":"2021","journal-title":"Life Sci"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1249\/MSS.0000000000000518","article-title":"Physiology of sedentary behavior and its relationship to health outcomes","volume":"47","author":"Thyfault","year":"2015","journal-title":"Med Sci Sports Exerc"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.02.006","article-title":"Exercise retards hepatocarcinogenesis in obese mice independently of weight control","volume":"73","author":"Arfianti","year":"2020","journal-title":"J Hepatol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1007\/s40200-019-00475-2","article-title":"Mediterranean diet for patients with non-alcoholic fatty liver disease, a systematic review and meta-analysis of observational and clinical investigations","volume":"19","author":"Akhlaghi","year":"2020","journal-title":"J Diabetes Metab Disord"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-323106","article-title":"Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial","volume":"70","author":"Yaskolka Meir","year":"2021","journal-title":"Gut"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1111\/liv.13435","article-title":"The Mediterranean dietary pattern as the diet of choice for non-alcoholic fatty liver disease: Evidence and plausible mechanisms","volume":"37","author":"Zelber-Sagi","year":"2017","journal-title":"Liver Int"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2013.08.014","article-title":"Adherence to the Mediterranean diet is associated with the severity of non-alcoholic fatty liver disease","volume":"33","author":"Kontogianni","year":"2014","journal-title":"Clin Nutr"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1007\/s12603-016-0809-8","article-title":"Effect of a low glycemic index Mediterranean diet on non-alcoholic fatty liver disease. A randomized controlled clinici trial","volume":"21","author":"Misciagna","year":"2017","journal-title":"J Nutr Health Aging"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1017\/S000711451800137X","article-title":"Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial","volume":"120","author":"Katsagoni","year":"2018","journal-title":"Br J Nutr"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2022.06.037","article-title":"The effectiveness and acceptability of Mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis","volume":"41","author":"Haigh","year":"2022","journal-title":"Clin Nutr"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.cmet.2024.04.015","article-title":"A 5:2 intermittent fasting regimen ameliorates NASH and fibrosis and blunts HCC development via hepatic PPAR\u03b1 and PCK1","volume":"36","author":"Gallage","year":"2024","journal-title":"Cell Metab"},{"key":"B119","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.cgh.2017.04.039","article-title":"Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: a systematic review and meta-analysis","volume":"15","author":"Kim","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.02.019","article-title":"PPAR\u03b1 gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis","volume":"63","author":"Francque","year":"2015","journal-title":"J Hepatol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/NEJMc1006581","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"363","author":"Violi","year":"2010","journal-title":"N Engl J Med"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21010360","article-title":"Antrodan Alleviates High-Fat and High-Fructose Diet-Induced Fatty Liver Disease in C57BL\/6 Mice Model via AMPK\/Sirt1\/SREBP-1c\/PPAR\u03b3 Pathway","volume":"21","author":"Chyau","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jafc.1c03105","article-title":"Regulation on citrate influx and metabolism through inhibiting SLC13A5 and ACLY: a novel mechanism mediating the therapeutic effects of curcumin on NAFLD","volume":"69","author":"Sun","year":"2021","journal-title":"J Agric Food Chem"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jafc.0c00148","article-title":"Theaflavin TF3 relieves hepatocyte lipid deposition through activating an AMPK signaling pathway by targeting plasma kallikrein","volume":"68","author":"Zhang","year":"2020","journal-title":"J Agric Food Chem"},{"key":"B128","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1080\/17474124.2022.2119128","article-title":"Statins decrease overall mortality and cancer related mortality but are underutilized in NAFLD: a longitudinal analysis of 12,538 individuals","volume":"16","author":"Ng","year":"2022","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2023.155183","article-title":"Shenge formula attenuates high-fat diet-induced obesity and fatty liver via inhibiting ACOX1","volume":"123","author":"Shang","year":"2024","journal-title":"Phytomedicine"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2024.155776","article-title":"Xiezhuo Tiaozhi formula inhibits macrophage pyroptosis in the non-alcoholic fatty liver disease by targeting the SIRT1 pathway","volume":"131","author":"Tian","year":"2024","journal-title":"Phytomedicine"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-031-63657-8_5","article-title":"Mechanism of obesity-related lipotoxicity and clinical perspective","volume":"1460","author":"Engin","year":"2024","journal-title":"Adv Exp Med Biol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13695","article-title":"Adipose tissue insulin resistance and lipidome alterations as the characterizing factors of non-alcoholic steatohepatitis","volume":"52","author":"Guerra","year":"2022","journal-title":"Eur J Clin Invest"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.10.023","article-title":"Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH","volume":"78","author":"Ratziu","year":"2023","journal-title":"J Hepatol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.91438","article-title":"Hammerhead-type FXR agonists induce an enhancer RNA Fincor that ameliorates nonalcoholic steatohepatitis in mice","volume":"13","author":"Chen","year":"2024","journal-title":"eLife"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S524893","article-title":"Therapeutic targeting of PPAR\u03b3 in nonalcoholic fatty liver disease: efficacy, safety, and drug development","volume":"19","author":"Zhou","year":"2025","journal-title":"Drug Des Devel Ther"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12081876","article-title":"Application of PPAR ligands and nanoparticle technology in metabolic steatohepatitis treatment","volume":"12","author":"Vu","year":"2024","journal-title":"Biomedicines"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat Med"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100237","article-title":"Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis","volume":"3","author":"Bhattacharya","year":"2021","journal-title":"JHEP Rep"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1597995","article-title":"Interaction mechanism and intervention strategy between metabolic dysfunction-associated steatotic liver disease and intestinal microbiota","volume":"16","author":"Yang","year":"2025","journal-title":"Front Microbiol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1785178\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:39:26Z","timestamp":1773812366000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1785178\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":139,"alternative-id":["10.3389\/fendo.2026.1785178"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1785178","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"article-number":"1785178"}}